146,332 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Acquired by Foresite Capital Management VI LLC

Foresite Capital Management VI LLC bought a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 146,332 shares of the company's stock, valued at approximately $5,887,000. Kymera Therapeutics makes up about 2.6% of Foresite Capital Management VI LLC's investment portfolio, making the stock its 12th biggest position. Foresite Capital Management VI LLC owned approximately 0.23% of Kymera Therapeutics as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Northern Trust Corp grew its position in shares of Kymera Therapeutics by 14.0% during the 4th quarter. Northern Trust Corp now owns 437,833 shares of the company's stock valued at $17,614,000 after acquiring an additional 53,658 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Kymera Therapeutics by 14.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 147,296 shares of the company's stock worth $5,926,000 after buying an additional 19,029 shares during the period. Aquatic Capital Management LLC purchased a new position in shares of Kymera Therapeutics during the 4th quarter valued at approximately $782,000. Susquehanna Fundamental Investments LLC acquired a new stake in Kymera Therapeutics in the 4th quarter valued at $2,391,000. Finally, Gilder Gagnon Howe & Co. LLC raised its position in Kymera Therapeutics by 12.0% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 326,349 shares of the company's stock worth $13,129,000 after acquiring an additional 35,009 shares during the period.

Insider Buying and Selling at Kymera Therapeutics

In related news, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. This trade represents a 3.37 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ellen Chiniara sold 2,241 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the sale, the insider now directly owns 80,085 shares in the company, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,659 shares of company stock worth $324,567 over the last three months. Insiders own 15.82% of the company's stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. HC Wainwright lifted their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Citigroup assumed coverage on Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 target price for the company. Finally, Stephens reiterated an "overweight" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $56.36.

Kymera Therapeutics Price Performance

KYMR traded up $0.73 during trading hours on Friday, reaching $35.28. The company's stock had a trading volume of 640,377 shares, compared to its average volume of 556,208. The business's 50-day moving average is $29.66 and its 200-day moving average is $38.32. The stock has a market cap of $2.29 billion, a PE ratio of -15.08 and a beta of 2.22. Kymera Therapeutics, Inc. has a fifty-two week low of $19.45 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The business had revenue of $7.39 million for the quarter, compared to analysts' expectations of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.